The Latest Breaking News from FDA

Plus: New developments in the Texas abortion drug ruling, fallout from the Riley Gaines event at SFSU, and more...

At the heart of the latest battle over abortion access is a federal judge’s ruling that cites concern about the mental health of women who choose to end their pregnancies.

Mifepristone will remain on the market, but approved only for use up to seven weeks of pregnancy, versus 10 weeks, and it cannot be prescribed by telehealth or mailed, which were already illegal in Texas.

The Biden administration had asked the higher court to stay a decision from a Texas judge while the appeal plays out.

A federal appeals court allowed the nation’s most-used medication abortion drug to remain on the market after Saturday.

People are seeking the advance provision of medication before Friday’s deadline, when the drug may become unavailable

An appeals court ruling prevents an outright ban on mifepristone, but the conservative panel has effectively made the drug harder for millions of Americans to obtain

The chiefs of more than 400 pharmaceutical companies signed a scathing letter this week blasting federal Judge Matthew Kacsmaryk’s ruling that the Food and Drug Administration had overstepped its authority in approving the abortion-inducing drug mifepristone. The letter was more than justified and, while harshly worded, accurately recounted Kacsmaryk’s abysmal…

Mark my words: Contraception is the next front in the war on women. And we can't say we haven't been warned.

A federal appeals court has preserved access to an abortion drug for now but under tighter rules that would allow the drug only to be dispensed up to seven weeks, not 10, and not by mail.

A federal appeals court has preserved access to an abortion drug for now but under tighter rules that would allow the drug only to be dispensed up to seven weeks, not 10, and not by mail